International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2022 - IJCMAS--ICV 2022: 95.28 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020] For more details click here

Login as a Reviewer

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles                      Volume : 5, Issue:5, May, 2016

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : /
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2016.5(5): 54-62

Interferon-Alpha and Ribavirin-Induced Thyroid Dysfunction in Chronic Hepatitis C Egyptian Patients: Incidence and Association  
Elham Ahmed Hassan1*, Abeer Sharaf El-din Abd El-rehim1, Mona Mohamed Abdel Maguid2, Khaled Abdel Azeem Eed3, Hamdy Mahfouz Mostafa3, Medhat Araby Khaled Saleh4 and Dina Shehata El-Azab5
1Department of Tropical Medicine and Gastroenterology, Faculty of Medicine,Assiut University, Assiut, Egypt
2Department of Clinical and Chemical Pathology, Faculty of Medicine, South Valley University, South Valley, Egypt
3Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Alazhar University, Assiut, Egypt
4Department of Public Health and Community Medicine, Faculty of Medicine,
Assiut University, Assiut, Egypt
5Department of Pathology, National Liver Institute, Menoufia University, Menoufia, Egypt
*Corresponding author

Thyroid dysfunction (TD) represents an extrahepatic manifestation of chronic hepatitis C.  This study aimed to assess TD incidence and association with disease severity, pretreatment viral load, pegylated interferon alpha 2a or 2b formulations and response to treatment in chronic hepatitis C patients treated with pegylated interferon alpha and Ribavirin. TD was prospectively evaluated in 226 euthyroid chronic hepatitis C Egyptian patients treated with pegylated interferon-alpha and Ribavirin for 48 weeks at weeks 0,4,12, 24, 36 and 48 of treatment and within 6 months after treatment using serum free thyroxine, thyroid-stimulating hormone. The disease severity and response to therapy were evaluated using METAVIR system and polymerase chain reaction test respectively. Twenty six treated patients (11.5%) developed TD (16 hypothyroidism, seven hyperthyroidism and three biphasic thyroiditis). 14 patients with TD achieved sustained viral response. 8/26 (30.8%) TD spontaneously reversed after treatment cessation and 18 cases required therapy. TD was not associated with pretreatment viral load, severity of liver fibrosis, interferon-alpha formulations or response to treatment. We conclude that Interferon-alpha and ribavirin therapy possibly induces TD in chronic hepatitis C patients. TD does not associate with pretreatment virological parameter, severity of liver disease or virological outcome.

Keywords: Thyroid dysfunction, Chronic hepatitis C, Peginterferon, Ribavirin.

Download this article as Download

How to cite this article:

Elham Ahmed Hassan, Abeer Sharaf El-din Abd El-rehim, Mona Mohamed Abdel Maguid, Khaled Abdel Azeem Eed, Hamdy Mahfouz Mostafa, Medhat Araby Khaled Saleh and Dina Shehata El-Azab. 2016. Interferon-Alpha and Ribavirin-Induced Thyroid Dysfunction in Chronic Hepatitis C Egyptian Patients: Incidence and AssociationInt.J.Curr.Microbiol.App.Sci. 5(5): 54-62. doi:
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.